Enumeral Biomedical Holdings Inc.
Taking checkpoint inhibition to the next level
This article was originally published in Start Up
Checkpoint inhibitors have caused a sensation in oncology in recent years, but biotech Enumeral Biomedical Holdings Inc. is setting its sights on the Achilles' heel of the new antibodies – the high failure rate – using a discovery platform that employs cells from human biopsies, rather than more commonly used rodent models.
Register for our free email digests: